LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

32.52 0.87

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

32.07

Максимум

32.88

Ключови измерители

By Trading Economics

Приходи

7.7M

-41M

Продажби

3.5M

110M

Марж на печалбата

-37.032

Служители

1,869

EBITDA

1.4M

-55M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+66.38% upside

Дивиденти

By Dow Jones

Следващи печалби

11.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-622M

3.6B

Предишно отваряне

31.65

Предишно затваряне

32.52

Настроения в новините

By Acuity

100%

0%

360 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.09.2025 г., 17:03 ч. UTC

Значими двигатели на пазара

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16.09.2025 г., 16:49 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

GD Culture Shares Drop After Deal for Pallas Capital

16.09.2025 г., 16:11 ч. UTC

Значими двигатели на пазара

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16.09.2025 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Decline as Yen Strengthens -- Market Talk

16.09.2025 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16.09.2025 г., 23:20 ч. UTC

Пазарно говорене

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16.09.2025 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16.09.2025 г., 20:51 ч. UTC

Пазарно говорене

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

16.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

16.09.2025 г., 20:25 ч. UTC

Печалби

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16.09.2025 г., 20:24 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16.09.2025 г., 19:19 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16.09.2025 г., 18:52 ч. UTC

Пазарно говорене

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16.09.2025 г., 18:44 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.09.2025 г., 18:44 ч. UTC

Пазарно говорене

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16.09.2025 г., 18:40 ч. UTC

Придобивния, сливания и поглъщания

Details Emerge on U.S.-China TikTok Deal -- WSJ

16.09.2025 г., 18:38 ч. UTC

Пазарно говорене

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16.09.2025 г., 18:19 ч. UTC

Пазарно говорене

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16.09.2025 г., 18:01 ч. UTC

Пазарно говорене

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16.09.2025 г., 17:34 ч. UTC

Пазарно говорене

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16.09.2025 г., 16:53 ч. UTC

Печалби

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16.09.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

16.09.2025 г., 16:15 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Commodities Roundup: Market Talk

16.09.2025 г., 16:09 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Energy Roundup: Market Talk

16.09.2025 г., 16:09 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16.09.2025 г., 15:35 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.09.2025 г., 15:35 ч. UTC

Пазарно говорене

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16.09.2025 г., 15:22 ч. UTC

Пазарно говорене

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16.09.2025 г., 15:21 ч. UTC

Пазарно говорене

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

66.38% нагоре

12-месечна прогноза

Среден 53.74 USD  66.38%

Висок 69 USD

Нисък 39 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

7

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat